#ASCO22: In yet another stinging setback, Pfizer's blockbuster CDK 4/6 fails its latest test on survival. But can Novartis and Eli Lilly benefit? - Endpoints News

In the latest in a series of big clinical setbacks, Pfizer reported at ASCO that its closely watched PALOMA-2 Phase III study of Ibrance combined with the chemo hormone therapy Femara (letrozole) failed to significantly move the dial on survival for first-lin…

In an ongoing, 18-person study, every single patient that has completed treatment saw their rectal cancer completely disappear. None of them needed chemotherapy, radiation, or surgery — the combinat… [+556 chars]

full article...